Report Sections

See All Reports

  • HP:0001677: Coronary artery atherosclerosis
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001677: Coronary artery atherosclerosis

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (38)


    Name (Synonyms) Correlation
    drug3390 Robot Assisted Percutaneous Cardiovascular Intervention Wiki 0.33
    drug3080 PressureWire X Wiki 0.33
    drug3342 Resolute Onyx Wiki 0.33
    Name (Synonyms) Correlation
    drug3805 Supera 7.5 OD stent Wiki 0.33
    drug1870 ISIS 721744 Wiki 0.33
    drug299 Anthocyanins Wiki 0.33
    drug288 Angiography Wiki 0.33
    drug1873 IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care. Wiki 0.33
    drug215 Ad5FGF-4 Wiki 0.33
    drug2803 Pacel BPC Wiki 0.33
    drug1872 IV Dexamethasone Wiki 0.33
    drug2804 Pacel FDPC Wiki 0.33
    drug2258 MULTI-LINK 8 LL stent Wiki 0.33
    drug2437 Motivational social support from nurse with additional support from significant other Wiki 0.33
    drug1882 Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Wiki 0.33
    drug2436 Motivational social support from nurse Wiki 0.33
    drug2501 Nasal Dexamethasone Wiki 0.33
    drug158 AVP 4 Wiki 0.33
    drug396 Attention control Wiki 0.33
    drug4322 Xpert Pro stent Wiki 0.33
    drug185 Absolute Pro LL stent Wiki 0.33
    drug26 12 weeks of bicycle exercise Wiki 0.33
    drug3918 Tele-medicine platform Wiki 0.33
    drug1881 Icosapent ethyl (IPE) Wiki 0.33
    drug1291 DynamX Bioadaptor Wiki 0.33
    drug3165 QFR Wiki 0.33
    drug2259 MULTI-LINK 8 SV stent Wiki 0.33
    drug159 AVP I Wiki 0.33
    drug160 AVP II Wiki 0.33
    drug4319 XIENCE PRIME BTK stent Wiki 0.33
    drug2260 MULTI-LINK 8 stent Wiki 0.33
    drug1880 Icosapent ethyl Wiki 0.24
    drug545 Best Practice Wiki 0.15
    drug2616 Normal Saline Wiki 0.14
    drug514 Baricitinib Wiki 0.13
    drug1193 Dexamethasone Wiki 0.11
    drug4025 Tocilizumab Wiki 0.05
    drug2916 Placebo Wiki 0.04

    Correlated MeSH Terms (25)


    Name (Synonyms) Correlation
    D003324 Coronary Artery Disease NIH 1.00
    D009203 Myocardial Ischemia NIH 0.52
    D000787 Angina Pectoris NIH 0.47
    Name (Synonyms) Correlation
    D007511 Ischemia NIH 0.47
    D003327 Coronary Disease NIH 0.38
    D023921 Coronary Stenosis NIH 0.33
    D023903 Coronary Restenosis NIH 0.33
    D060050 Angina, Stable NIH 0.33
    D006331 Heart Diseases NIH 0.27
    D054143 Heart Failure, Systolic NIH 0.24
    D054058 Acute Coronary Syndrome NIH 0.14
    D007676 Kidney Failure, Chronic NIH 0.13
    D003704 Dementia NIH 0.12
    D007238 Infarction NIH 0.10
    D006333 Heart Failure NIH 0.10
    D008173 Lung Diseases, Obstructive NIH 0.09
    D029424 Pulmonary Disease, Chronic Obstructive NIH 0.09
    D060825 Cognitive Dysfunction NIH 0.09
    D020521 Stroke NIH 0.08
    D004617 Embolism NIH 0.08
    D002318 Cardiovascular Diseases NIH 0.06
    D007249 Inflammation NIH 0.06
    D009369 Neoplasms, NIH 0.06
    D013577 Syndrome NIH 0.03
    D007239 Infection NIH 0.02

    Correlated HPO Terms (11)


    Name (Synonyms) Correlation
    HP:0001658 Myocardial infarction HPO 0.52
    HP:0001681 Angina pectoris HPO 0.47
    HP:0005145 Coronary artery stenosis HPO 0.33
    Name (Synonyms) Correlation
    HP:0000726 Dementia HPO 0.12
    HP:0001635 Congestive heart failure HPO 0.10
    HP:0006536 Pulmonary obstruction HPO 0.09
    HP:0001268 Mental deterioration HPO 0.09
    HP:0006510 Chronic pulmonary obstruction HPO 0.09
    HP:0001297 Stroke HPO 0.08
    HP:0001626 Abnormality of the cardiovascular system HPO 0.06
    HP:0002664 Neoplasm HPO 0.06

    Clinical Trials

    Navigate: Correlations   HPO

    There are 9 clinical trials


    1 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia

    The purpose of this study is to determine whether a single intracoronary infusion of an adenovirus serotype 5 virus expressing the gene for human fibroblast growth factor-4 (Ad5FGF-4) is effective in improving angina-limited exercise duration, angina functional class, frequency of angina attacks, frequency of nitroglycerin usage, and quality of life. Half of the study participants will receive Ad5FGF-4, and half will receive placebo. The primary endpoint is the change from baseline to Month 6 in Exercise Tolerance Test (ETT) duration. Long-term safety of Ad5FGF-4 will also be assessed.

    NCT02928094
    Conditions
    1. Angina, Stable
    Interventions
    1. Biological: Ad5FGF-4
    2. Biological: Placebo
    MeSH:Angina Pectoris Myocardial Ischemia Coronary Artery Disease Angina, Stable Ischemia
    HPO:Angina pectoris Coronary artery atherosclerosis Myocardial infarction

    Primary Outcomes

    Description: Modified Bruce Protocol with exercise duration limited by angina or angina equivalent

    Measure: Change in Exercise Tolerance Test (ETT) duration

    Time: Baseline and Month 6

    Secondary Outcomes

    Description: Canadian Cardiovascular Society (CCS) angina classification

    Measure: Change in patient functional status (CCS class)

    Time: Baseline and Month 6

    Description: Average weekly angina episodes

    Measure: Change in weekly angina frequency

    Time: Baseline and Month 6

    Description: Average weekly nitroglycerin usage

    Measure: Change in weekly nitroglycerin usage

    Time: Baseline and Month 6

    Description: Seattle Angina Questionnaire

    Measure: Change in quality of life

    Time: Baseline and Month 6

    Description: Adverse events and clinical laboratory testing

    Measure: Safety of Ad5FGF-4

    Time: Through Month 6

    Description: Occurrence of clinically significant events

    Measure: Long-term safety of Ad5FGF-4

    Time: Through Month 60
    2 A Randomized, 24-week Parallel-group Placebo-controlled Multicenter (Phase 2) Study of Anthocyanins in People at Risk for Dementia

    The aim of this project is to study the safety and efficacy of anthocyanins in improving key dementia-related mechanisms and cognitive functioning in older people at risk for dementia. Secondary analyses will include a variety of biological measures, including biochemistry, imaging and cardiovascular measures.

    NCT03419039
    Conditions
    1. Dementia
    2. Inflammation
    3. Mild Cognitive Impairment
    4. Coronary Artery Disease
    Interventions
    1. Dietary Supplement: Anthocyanins
    2. Dietary Supplement: Placebo
    MeSH:Dementia Coronary Artery Disease Inflammation Cognitive Dysfunction
    HPO:Cognitive impairment Coronary artery atherosclerosis Dementia Mental deterioration

    Primary Outcomes

    Description: A composite measure from the CogTrack battery

    Measure: Quality of episodic memory.

    Time: Baseline to 24 weeks

    Secondary Outcomes

    Description: CogTrack evaluates attentional intensity index, sustained intensity index, cognitive reaction time, attentional fluctuation index, quality of working memory, quality of episodic memory and speed of memory retrieval.

    Measure: Secondary endpoints from CogTrack

    Time: Baseline to 24 weeks

    Description: Lipid profile, fatty acids, cytokines ( among others: IL-1, IL-2, IL-6, TNF-a), plasma antoxidant status and vitamins (lipid peroxidation markers, vitamins E, C, A, total plasma antioxidant capacity, glutathion)., carinthine, blood glucose, HbA1c, anthocyanins and metabolites, mapping of a-beta degradation products.

    Measure: Blood outcome analysis

    Time: Baseline to 24 weeks

    Description: Flow-mediated dilation (FMD), Cardiac-ankle vascular index (CAVI), photoplethysmogram (PPG).

    Measure: Cardiovascular parameters

    Time: Baseline to 24 weeks

    Description: Microbiota

    Measure: Fecal analysis

    Time: Baseline to 24 weeks

    Description: kyrinin

    Measure: Urine analysis

    Time: Baseline to 24 weeks

    Description: anthocyanin metabolites

    Measure: CSF measurements

    Time: Baseline to 24 weeks

    Description: Diagnosing and follow-up of cerebrovascular disease

    Measure: MR-imaging/CT

    Time: Baseline to 24 weeks
    3 Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous InterVention in Patients With cORonary Artery Disease (The FAVOR III China Study)

    The overall purpose of the FAVOR III China trial is to investigate if a strategy of quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) yields superior clinical outcome and cost-effectiveness compared to a strategy of standard coronary angiography-guided PCI in evaluation of patients with coronary artery disease.

    NCT03656848
    Conditions
    1. Coronary Artery Disease
    2. Myocardial Ischaemia
    3. Coronary Circulation
    4. Coronary Stenosis
    5. Percutaneous Coronary Intervention
    Interventions
    1. Diagnostic Test: QFR
    2. Diagnostic Test: Angiography
    MeSH:Coronary Artery Disease Myocardial Ischemia Coronary Disease Coronary Stenosis Ischemia
    HPO:Coronary artery atherosclerosis Coronary artery stenosis Myocardial infarction

    Primary Outcomes

    Description: A composite of all-cause mortality, any myocardial infarction and any ischemia-driven revascularization

    Measure: MACE

    Time: 1 year

    Secondary Outcomes

    Description: all-cause mortality, any spontaneous myocardial infarction and any ischemia-driven revascularization

    Measure: MACE excluding peri-procedural MI (Major secondary endpoint)

    Time: 1 year

    Description: Cardiovascular, non-cardiovascular and undetermined death

    Measure: Death

    Time: 1 month, 6 months, 1 year, 2 years and 3 years

    Description: Target vessel related and non-target vessel related MI

    Measure: MI

    Time: 1 month, 6 months, 1 year, 2 years and 3 years

    Description: The ischemia driven and non-ischemia driven TVR

    Measure: Target vessel revascularization (TVR)

    Time: 1 month, 6 months, 1 year, 2 years and 3 years

    Description: The The ischemia driven and non-ischemia driven Revascularization

    Measure: Any coronary artery revascularization

    Time: 1 month, 6 months, 1 year, 2 years and 3 years

    Description: Definite and probable stent thrombosis during acute, sub-acute, late, and very late phase according to the Academic Research Consortium (ARC)-2

    Measure: Definite or probable stent thrombosis

    Time: 1 month, 6 months, 1 year, 2 years and 3 years

    Description: PCI strategy changes following QFR and three-dimension quantitative coronary angiography (3D-QCA)

    Measure: The PCI strategy changes based on the QFR and 3D-QCA

    Time: During the procedure

    Description: Costs include direct clinical costs during the initial hospitalization and other resources used, main cardiovascular medication expenses, and outpatient and/or hospitalization expenses associated with MACE.

    Measure: Cost during 1-year follow-up

    Time: 1 month, 6 months, 1 year

    Description: QALYs determined using EuroQol five dimensions questionnaire (EQ-5D) in official Chinese version, to assess the quality of life.

    Measure: Quality-adjusted-life-years (QALYs) index

    Time: 1 month, 6 months, 1 year
    4 A Randomized Controlled Trial to Reduce Hopelessness Through Enhanced Physical Activity in Adults With Ischemic Heart Disease

    After a 30-year decline, heart disease is projected to increase up to 18% by 2030. Participation rates in cardiac rehabilitation remain extremely low and hopeless individuals are less likely to participate. This innovative study has the potential to advance science, improve patient care, and improve patient outcomes by demonstrating the effectiveness of the Heart Up! program to increase physical activity and reduce hopelessness in patients with heart disease. Hopelessness is associated with a 3.4 times increased risk of mortality or nonfatal myocardial infarction in patients with ischemic heart disease (IHD), independent of depression. Hopelessness has been identified in 27-52% of patients with IHD and can persist for up to 12 months after hospital discharge. Hopelessness, a negative outlook and sense of helplessness toward the future, can be a temporary response to an event (state) or a habitual outlook (trait). Hopelessness is associated with decreased physical functioning and lower physical activity (PA) levels in individuals with IHD. While research has investigated strategies to increase PA among IHD patients in general, the study team is the only group to design an intervention to promote PA specifically in hopeless IHD patients. The purpose of this randomized controlled trial is to establish the effectiveness of our 6-week mHealth intervention (Heart Up!) to promote increased PA in hopeless patients with IHD. A total of 225 hopeless IHD patients will be enrolled from a large community teaching hospital in the Midwest. Patients will be randomized (75 per group) to one of three groups: 1) motivational social support (MSS) from a nurse, 2) MSS from a nurse with additional significant other support (SOS), or 3) attention control (AC). It is hypothesized that 1) The MSS with SOS group will have the greatest increase in average minutes of moderate to vigorous PA per day at 8 and 24 weeks as compared to the MSS only or AC groups; 2) Greater increase in minutes of moderate to vigorous PA per day will be associated with decreased state hopelessness levels from baseline to weeks 8 and 24; and 3) Increased social support and increased motivation will mediate the effects of Heart Up! on a greater increase in moderate to vigorous PA at 8 and 24 weeks. The findings from this study could transform care for IHD patients who are hopeless by promoting self-management of important PA goals that can contribute to better health outcomes.

    NCT03907891
    Conditions
    1. Ischemic Heart Disease
    2. Hopelessness
    3. Physical Activity
    4. Motivation
    5. Social Support
    6. Covid19
    Interventions
    1. Behavioral: Motivational social support from nurse
    2. Behavioral: Motivational social support from nurse with additional support from significant other
    3. Behavioral: Attention control
    MeSH:Heart Diseases Myocardial Ischemia Coronary Artery Disease Ischemia
    HPO:Coronary artery atherosclerosis Myocardial infarction

    Primary Outcomes

    Description: Mean minutes/day moderate to vigorous physical activity

    Measure: ActiGraph GT9X Link Accelerometer

    Time: Month 12

    Description: Participant's report of current level of state hopelessness. Total score range= 1 (better) to 4 (worse).

    Measure: State-Trait Hopelessness Scale

    Time: Month 12

    Secondary Outcomes

    Description: Participant's report of exercise self-regulation level. Total score range= 1 (worse) to 7 (better).

    Measure: Exercise Self-Regulation Questionnaire

    Time: Month 12

    Description: Participant's report of perceived social support level. Total score range= 1 (worse) to 30 (better).

    Measure: ENRICHD Social Support Inventory

    Time: Month 12

    Other Outcomes

    Description: Comorbidity score based on medical record abstraction. Total score range= 0 (better) to 100 (worse).

    Measure: Charlson Comorbidity Index

    Time: Week 1

    Description: Participant's report of participation level with exercise in home, community or cardiac rehabilitation program

    Measure: Cardiac Rehabilitation Exercise Participation Tool

    Time: Month 12

    Description: Participant's report of mean level of depressive symptoms. Total score range= 0 (better) to 27 (worse).

    Measure: Patient Health Questionnaire-9

    Time: Month 12

    Description: Participant's report of mean level of well-being. Total score range= 4 (better) to 20 (worse).

    Measure: PROMIS-29

    Time: Month 12

    Description: Participant's report of mean level state and trait hope. Total score range= 8 (worse) to 64 (better).

    Measure: Snyder State Trait Scales

    Time: Month 12

    Description: Participant's report of mean level of quality of life. Total score range= 1 (better) to 5 (worse).

    Measure: EuroQol (EQ-5d-5L)

    Time: Month 12

    Description: Participant's report of COVID-19 symptoms, diagnosis, testing, and social distancing. No score range (14 items).

    Measure: Multi-Ethnic Study of Atherosclerosis (MESA) COVID-19 Questionnaire

    Time: Month 12

    Description: Participant's report of impact on routine; income/ employment; access to food, medical and mental health care, extended family; and stress. No range (12 items)

    Measure: Coronavirus Impact Scale

    Time: Month 12
    5 Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic

    Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.

    NCT04325867
    Conditions
    1. Angina Pectoris
    2. Acute Coronary Syndrome
    3. Coronary Syndrome
    4. Coronary Artery Disease
    5. Angioplasty
    6. Stent Restenosis
    7. Hypertension
    8. Heart Failure, Systolic
    9. Depression, Anxiety
    10. Covid-19
    11. Isolation, Social
    Interventions
    1. Other: Tele-medicine platform
    MeSH:Heart Failure Cardiovascular Diseases Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Angina Pectoris Heart Failure, Systolic Syndrome
    HPO:Abnormal left ventricular function Abnormality of the cardiovascular system Angina pectoris Congestive heart failure Coronary artery atherosclerosis Myocardial infarction Right ventricular failure

    Primary Outcomes

    Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context

    Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients

    Time: 6 months

    Description: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);

    Measure: Number of patients included in this platform

    Time: 6 months

    Secondary Outcomes

    Description: Will be the number of sessions per patient multiplied with the number of patients included

    Measure: Number of consultations/sessions given

    Time: 6 months
    6 Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial

    This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

    NCT04361552
    Conditions
    1. Cerebrovascular Accident
    2. Chronic Obstructive Pulmonary Disease
    3. Chronic Renal Failure
    4. Coronary Artery Disease
    5. Diabetes Mellitus
    6. Malignant Neoplasm
    7. SARS Coronavirus 2 Infection
    Interventions
    1. Other: Best Practice
    2. Biological: Tocilizumab
    MeSH:Infection Neoplasms Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Stroke Kidney Failure, Chronic Coronary Artery Disease
    HPO:Chronic pulmonary obstruction Coronary artery atherosclerosis Neoplasm Pulmonary obstruction Stroke

    Primary Outcomes

    Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.

    Measure: 7-day length of invasive mechanical ventilation (MV)

    Time: Up to 7 days

    Description: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: 30-day mortality rate

    Time: Up to 30-day after randomization

    Secondary Outcomes

    Description: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of intensive care (ICU) transfer

    Time: Up to 2 years

    Description: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of invasive mechanical ventilation

    Time: Up to 2 years

    Description: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of tracheostomy

    Time: Up to 2 years

    Description: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test

    Measure: Length of ICU stay

    Time: Up to 2 years

    Measure: Length of hospital stay

    Time: Up 2 years
    7 Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses

    Percutaneous cardiovascular intervention procedures (e.g. coronary angioplasty, peripheral artery angioplasty) must be performed in person, requiring the physical presence of one or more medical, nursing and technical professionals. The control of catheters and interventional materials is performed manually, with the operator positioned next to the patient. This context results in potential for reciprocal exposure to exhaled air, both for the professionals involved and for the patient, with an inherent risk of aerial contamination. It is important to note that interventional procedures are often performed on an urgent or emergency basis (e.g. myocardial infarction), without the possibility of postponement or postponement. The recent robot-assisted cardiovascular intervention makes it possible to modify this scenario by allowing the procedure to be performed effectively and safely in a position far from the patient. In an environment with high potential for contamination, mainly related to the current pandemic caused by the COVID-19 virus, may prove to be a tactic to expand hospital security. It is in this sense that the present pilot proposal is inserted, which, ultimately, aims to evaluate the potential of robotic intervention as a strategy to reduce exposure to exhaled air of patients and professionals during the intervention procedure.

    NCT04379453
    Conditions
    1. Coronary Artery Disease
    Interventions
    1. Procedure: Robot Assisted Percutaneous Cardiovascular Intervention
    MeSH:Coronary Artery Disease Myocardial Ischemia Coronary Disease
    HPO:Coronary artery atherosclerosis Myocardial infarction

    Primary Outcomes

    Description: (arterial dilation with residual lesion <50% at angiography and normal anterograde flow)

    Measure: Successful cardiovascular intervention

    Time: Until the end of the procedure

    Measure: Performed with the professional team positioned at> 2 meters from the patient for at least 50% of the duration of the intervention

    Time: Until the end of the procedure

    Measure: absence of fatal complications caused by the procedure or acute non-fatal vessel occlusion during index admission

    Time: Until the end of the procedure
    8 Infinity-Swedeheart Study: Registry Based Randomized Clinical Trial (R-RCT) Comparing Long Term Outcomes of the DynamX Bioadaptor to the Resolute Onyx Stent in a More-comer PCI Patient Population

    The Infinity-Swedeheart trial is a prospective, multicenter, single-blind, randomized registry-based clinical trial. Eligible patients will be randomized 1:1 (DynamX Bioadaptor : Resolute Onyx).

    NCT04562805
    Conditions
    1. Coronary Artery Disease
    2. Ischemic Heart Disease
    Interventions
    1. Device: DynamX Bioadaptor
    2. Device: Resolute Onyx
    MeSH:Coronary Artery Disease Myocardial Ischemia Heart Diseases
    HPO:Coronary artery atherosclerosis Myocardial infarction

    Primary Outcomes

    Description: Device Oriented Clinical Endpoint (DOCE) of target lesion failure (TLF; cardiovascular death, target vessel myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (ID-TLR))

    Measure: Target Lesion Failure (TLF)

    Time: 1 year

    Secondary Outcomes

    Description: Lesion-Level Analysis

    Measure: Device Success

    Time: During Study Procedure

    Description: Patient-Level Analysis

    Measure: Procedural Success

    Time: In-Hospital, assessed up to 7 days

    Description: Composite Device Oriented Clinical Endpoint (DOCE) (TLF; cardiovascular death, TV-MI, ischemia-driven TLR)

    Measure: Composite Rate of Device Oriented Clinical Endpoint (DOCE)

    Time: 30 days, 6 months, 1-5 years

    Description: Composite Patient Oriented Clinical Endpoint (POCE) (all-cause mortality, any stroke, any myocardial infarction (includes non-target vessel territory) and any revascularization). Note: Stroke to be collected and included in the POCE at 1 year and 5 years only.

    Measure: Composite Rate of Patient Oriented Clinical Endpoint (POCE)

    Time: 30 days, 6 months, 1-5 years

    Description: Target vessel failure (TVF; cardiovascular death, target vessel myocardial infarction (TV-MI), or target vessel revascularization (TVR))

    Measure: Rate of Target Vessel Failure (TVF)

    Time: 30 days, 6 months, 1-5 years

    Description: Composite of cardiovascular death, any myocardial infarction and any revascularization

    Measure: Composite Rate of cardiovascular death, any myocardial infarction and any revascularization

    Time: 30 days, 6 months, 1-5 years

    Description: Ischemia driven target lesion revascularization (ID-TLR)

    Measure: Rate of Ischemia driven target lesion revascularization (ID-TLR)

    Time: 30 days, 6 months, 1-5 years

    Description: All Target Lesion Revascularization

    Measure: Rate of Target Lesion Revascularization (TLR)

    Time: 30 days, 6 months, 1-5 years

    Description: All Target Vessel Revascularization

    Measure: Rate of Target Vessel Revascularization (TVR)

    Time: 30 days, 6 months, 1-5 years

    Description: Ischemia driven target vessel revascularization (ID-TVR)

    Measure: Rate of Ischemia driven target vessel revascularization (ID-TVR)

    Time: 30 days, 6 months, 1-5 years

    Description: Ischemia driven non target vessel revascularization (ID-NTVR)

    Measure: Rate of Ischemia driven non target vessel revascularization (ID-NTVR)

    Time: 30 days, 6 months, 1-5 years

    Description: Non target vessel revascularization (NTVR)

    Measure: Rate of Non target vessel revascularization (NTVR)

    Time: 30 days, 6 months, 1-5 years

    Description: All revascularization

    Measure: Rate of All revascularization

    Time: 30 days, 6 months, 1-5 years

    Description: All MI, Q-Wave and Non Q-Wave MI, TV-MI, NTV-MI

    Measure: Rate of Myocardial Infarction

    Time: 30 days, 6 months, 1-5 years

    Description: Cardiovascular Death, All-Cause Death

    Measure: Rate of Death

    Time: 30 days, 6 months, 1-5 years

    Description: Composite: Cardiovascular death or myocardial infarction

    Measure: Composite: Cardiovascular death or myocardial infarction

    Time: 30 days, 6 months, 1-5 years

    Description: Composite: All-cause death or myocardial infarction

    Measure: Composite: All-cause death or myocardial infarction

    Time: 30 days, 6 months, 1-5 years

    Description: Composite: All-cause death, myocardial infarction or target vessel revascularization

    Measure: Composite: All-cause death, myocardial infarction or target vessel revascularization

    Time: 30 days, 6 months, 1-5 years

    Description: Any stroke (collected at 1 year and 5 years only)

    Measure: Rate of any stroke

    Time: 1 year and 5 years

    Description: Anginal Status by Seattle Angina Questionnaire-7 (SAQ-7)

    Measure: Anginal Status

    Time: 30 days and 1 year

    Description: Composite: Probable or definite stent thrombosis Probable Stent Thrombosis Definite Stent Thrombosis

    Measure: Rate of Stent Thrombosis

    Time: 30 days, 6 months, 1-5 years
    9 Abbott Vascular Medical Device Registry

    The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use with the aim of confirming safety and performance throughout their expected lifetime, ensuring the continued acceptability of identified risks, detecting emerging risks on the basis of factual evidence, ensuring the continued acceptability of the benefit-risk ratio, and identifying possible systematic misuse or off-label usage such that the intended use can be verified as appropriate.

    NCT04573660
    Conditions
    1. Critical Limb Ischemia
    2. Symptomatic Ischemic Heart Disease
    3. Acute Myocardial Infarction
    4. Restenoses, Coronary
    5. Coronary Artery Lesions
    6. Venous Embolism
    7. Arterial Embolism
    Interventions
    1. Device: XIENCE PRIME BTK stent
    2. Device: Absolute Pro LL stent
    3. Device: Supera 7.5 OD stent
    4. Device: Xpert Pro stent
    5. Device: Pacel BPC
    6. Device: Pacel FDPC
    7. Device: AVP I
    8. Device: AVP II
    9. Device: AVP 4
    10. Device: PressureWire X
    11. Device: MULTI-LINK 8 stent
    12. Device: MULTI-LINK 8 LL stent
    13. Device: MULTI-LINK 8 SV stent
    MeSH:Heart Diseases Myocardial Infarction Embolism Myocardial Ischemia Coronary Artery Disease Coronary Restenosis Infarction Ischemia
    HPO:Coronary artery atherosclerosis Myocardial infarction

    Primary Outcomes

    Description: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.

    Measure: Number of participants with composite of all-cause death, amputation, and TLR

    Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)

    Description: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.

    Measure: Number of participants with composite of all-cause death, amputation, and TLR

    Time: 30 days

    Description: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.

    Measure: Number of participants with composite of all-cause death, amputation, and TLR

    Time: 12 months

    Description: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.

    Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion

    Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)

    Description: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.

    Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion

    Time: 30 days

    Description: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.

    Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion

    Time: 12 months

    Description: Composite of potential complications including implant success,occlusion success, migration will be assessed among the patients whoreceive AVP or AVP II or AVP 4 and its competitors.

    Measure: Number of participants with composite of potential complications (Implant success, occlusion success,migration)

    Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)

    Description: Composite of vessel dissection, perforation, and thromboembolism during procedure will be assessed among the patients who receive PressureWire X and its competitors.

    Measure: Number of participants with composite of vessel dissection, perforation, and thromboembolism

    Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)

    Description: Signal drift (minimal pressure drift > 3 mmHg) will be assessed among the patients who receive PressureWire X and its competitors.

    Measure: Number of participants with signal drift (minimal pressure drift > 3 mmHg)

    Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)

    Description: Loss of capture (average time of loss of capture across patients) will be assessed among the patients who receive Pacel FDPC and its competitors.

    Measure: Loss of capture

    Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)

    Description: Composite of potential complications (venous thrombosis, pulmonaryemboli, arrhythmias, perforation) will be assessed among the patientswho receive Pacel BPC and its competitors.

    Measure: Number of participants with composite of potential complications (venous thrombosis, pulmonaryemboli, arrhythmias, perforation)

    Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)

    Description: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.

    Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR)

    Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)

    Description: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.

    Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR)

    Time: 30 days

    Description: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.

    Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR)

    Time: 12 months

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook